NZ548250A - Apicomplex vaccine strains of a family of Sarcocystidae - Google Patents
Apicomplex vaccine strains of a family of SarcocystidaeInfo
- Publication number
- NZ548250A NZ548250A NZ548250A NZ54825005A NZ548250A NZ 548250 A NZ548250 A NZ 548250A NZ 548250 A NZ548250 A NZ 548250A NZ 54825005 A NZ54825005 A NZ 54825005A NZ 548250 A NZ548250 A NZ 548250A
- Authority
- NZ
- New Zealand
- Prior art keywords
- micl
- strain
- mic3
- mutant
- mice
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 26
- 241000223929 Sarcocystidae Species 0.000 title claims abstract description 8
- 102100037904 CD9 antigen Human genes 0.000 claims abstract description 79
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims abstract description 78
- 230000035772 mutation Effects 0.000 claims abstract description 23
- 241000223997 Toxoplasma gondii Species 0.000 claims description 43
- 101100496087 Mus musculus Clec12a gene Proteins 0.000 claims description 40
- 241000223996 Toxoplasma Species 0.000 claims description 12
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 9
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims description 6
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 abstract description 5
- 101000692878 Homo sapiens Regulator of MON1-CCZ1 complex Proteins 0.000 abstract description 5
- 102100026436 Regulator of MON1-CCZ1 complex Human genes 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 55
- 210000004027 cell Anatomy 0.000 description 43
- 208000015181 infectious disease Diseases 0.000 description 38
- 239000013612 plasmid Substances 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 35
- 210000000059 tachyzoite Anatomy 0.000 description 28
- 206010000210 abortion Diseases 0.000 description 26
- 231100000176 abortion Toxicity 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 244000045947 parasite Species 0.000 description 20
- 230000001018 virulence Effects 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 230000035935 pregnancy Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 208000012851 brain cyst Diseases 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 241000224482 Apicomplexa Species 0.000 description 9
- 208000031513 cyst Diseases 0.000 description 9
- 230000002779 inactivation Effects 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 9
- 230000002516 postimmunization Effects 0.000 description 9
- 241000283903 Ovis aries Species 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 238000003304 gavage Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000003250 oocyst Anatomy 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000008348 humoral response Effects 0.000 description 5
- 230000003071 parasitic effect Effects 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 210000003934 vacuole Anatomy 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 235000019687 Lamb Nutrition 0.000 description 4
- 208000035415 Reinfection Diseases 0.000 description 4
- 102220468330 Tektin-1_Y96A_mutation Human genes 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010020843 Hyperthermia Diseases 0.000 description 3
- 241001147660 Neospora Species 0.000 description 3
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 3
- 108010035235 Phleomycins Proteins 0.000 description 3
- 102220566441 Protein Hikeshi_F97A_mutation Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000036031 hyperthermia Effects 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 102220014839 rs139579816 Human genes 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000003463 Animal Toxoplasmosis Diseases 0.000 description 2
- 102220477229 C-X-C chemokine receptor type 4_Y135A_mutation Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000011795 OF1 mouse Methods 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 101100345585 Toxoplasma gondii MIC6 gene Proteins 0.000 description 2
- 241000504303 Toxoplasma gondii RH Species 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001938 anti-toxoplasmal effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000061 bradyzoite Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000009073 conformational modification Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 102000008482 12E7 Antigen Human genes 0.000 description 1
- 108010020567 12E7 Antigen Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000224003 Sarcocystis Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000026502 entry into host cell Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000029610 recognition of host Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 210000004929 secretory organelle Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003046 sporozoite Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0400260A FR2864966B1 (fr) | 2004-01-13 | 2004-01-13 | Souches vaccinales d'apicomplexes de la famille des sarcocystidae. |
| PCT/FR2005/000074 WO2005072754A1 (fr) | 2004-01-13 | 2005-01-13 | Souches vaccinales d'apicomplexes de la famille des sarcocystidae. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ548250A true NZ548250A (en) | 2010-09-30 |
Family
ID=34684953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ548250A NZ548250A (en) | 2004-01-13 | 2005-01-13 | Apicomplex vaccine strains of a family of Sarcocystidae |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7964185B2 (pl) |
| EP (1) | EP1703914B1 (pl) |
| JP (1) | JP4792402B2 (pl) |
| AT (1) | ATE392209T1 (pl) |
| AU (1) | AU2005207647B2 (pl) |
| BR (1) | BRPI0506838B8 (pl) |
| CA (1) | CA2552392C (pl) |
| DE (1) | DE602005006096T2 (pl) |
| DK (1) | DK1703914T3 (pl) |
| ES (1) | ES2306114T3 (pl) |
| FR (1) | FR2864966B1 (pl) |
| NZ (1) | NZ548250A (pl) |
| PL (1) | PL1703914T3 (pl) |
| PT (1) | PT1703914E (pl) |
| WO (1) | WO2005072754A1 (pl) |
| ZA (1) | ZA200605535B (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2994096B1 (fr) * | 2012-08-02 | 2016-03-04 | Vitamfero | Utilisation de souches attenuees de parasites pour la prevention ou le traitement de pathologies associees a un apicomplexe |
| FR2994193B1 (fr) * | 2012-08-02 | 2016-05-20 | Vitamfero | Souches mutantes de neospora et leurs utilisations |
| FR3002846B1 (fr) * | 2013-03-06 | 2016-03-25 | Vitamfero | Utilisation de souches attenuees de parasite pour la prevention et/ou le traitement de lesions oculaires associees a une infection par toxoplasma gondii |
| EP3142486B1 (en) | 2014-05-14 | 2026-03-11 | Boehringer Ingelheim Vetmedica GmbH | Methods for freeze-drying and rehydrating biologics |
| FR3068363A1 (fr) * | 2017-07-03 | 2019-01-04 | Vitamfero | Utilisation de souches de sarcocystidae dans la prevention de maladies infectieuses de la volaille |
| FR3068362A1 (fr) * | 2017-07-03 | 2019-01-04 | Vitamfero | Nouvelles souches attenuees d'apicomplexes et leur utilisation comme vecteurs d'antigene pour la prevention de maladies infectueuses |
| FR3068364A1 (fr) * | 2017-07-03 | 2019-01-04 | Vitamfero | Utilisation de souches de sarcocystidae comme vecteurs multirecombinants d'antigenes pour la prevention de maladies infectieuses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| FR2805466A1 (fr) * | 2000-02-25 | 2001-08-31 | Virsol | Utilisation de la proteine mic3 de toxoplasma gondii ou d'un de ses derives en tant qu'agent immunogene ou en tant qu'antigene de vaccination |
-
2004
- 2004-01-13 FR FR0400260A patent/FR2864966B1/fr not_active Expired - Fee Related
-
2005
- 2005-01-13 BR BRPI0506838A patent/BRPI0506838B8/pt not_active IP Right Cessation
- 2005-01-13 ES ES05717409T patent/ES2306114T3/es not_active Expired - Lifetime
- 2005-01-13 CA CA2552392A patent/CA2552392C/fr not_active Expired - Fee Related
- 2005-01-13 WO PCT/FR2005/000074 patent/WO2005072754A1/fr not_active Ceased
- 2005-01-13 US US10/585,721 patent/US7964185B2/en not_active Expired - Fee Related
- 2005-01-13 DK DK05717409T patent/DK1703914T3/da active
- 2005-01-13 NZ NZ548250A patent/NZ548250A/en not_active IP Right Cessation
- 2005-01-13 PL PL05717409T patent/PL1703914T3/pl unknown
- 2005-01-13 JP JP2006548351A patent/JP4792402B2/ja not_active Expired - Fee Related
- 2005-01-13 EP EP05717409A patent/EP1703914B1/fr not_active Expired - Lifetime
- 2005-01-13 AT AT05717409T patent/ATE392209T1/de active
- 2005-01-13 AU AU2005207647A patent/AU2005207647B2/en not_active Ceased
- 2005-01-13 DE DE602005006096T patent/DE602005006096T2/de not_active Expired - Lifetime
- 2005-01-13 PT PT05717409T patent/PT1703914E/pt unknown
-
2006
- 2006-07-05 ZA ZA200605535A patent/ZA200605535B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0506838B8 (pt) | 2021-05-25 |
| JP4792402B2 (ja) | 2011-10-12 |
| AU2005207647B2 (en) | 2011-02-10 |
| BRPI0506838A (pt) | 2007-06-12 |
| FR2864966B1 (fr) | 2006-05-05 |
| EP1703914B1 (fr) | 2008-04-16 |
| CA2552392C (fr) | 2014-04-22 |
| DK1703914T3 (da) | 2008-08-18 |
| FR2864966A1 (fr) | 2005-07-15 |
| EP1703914A1 (fr) | 2006-09-27 |
| CA2552392A1 (fr) | 2005-08-11 |
| JP2007524409A (ja) | 2007-08-30 |
| BRPI0506838B1 (pt) | 2016-02-23 |
| US20090053266A1 (en) | 2009-02-26 |
| AU2005207647A1 (en) | 2005-08-11 |
| ATE392209T1 (de) | 2008-05-15 |
| PT1703914E (pt) | 2008-07-24 |
| US7964185B2 (en) | 2011-06-21 |
| ZA200605535B (en) | 2008-03-26 |
| PL1703914T3 (pl) | 2009-06-30 |
| DE602005006096D1 (de) | 2008-05-29 |
| WO2005072754A1 (fr) | 2005-08-11 |
| DE602005006096T2 (de) | 2009-07-02 |
| ES2306114T3 (es) | 2008-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cérède et al. | Synergistic role of micronemal proteins in Toxoplasma gondii virulence | |
| Peng et al. | Toxoplasma gondii microneme protein 6 (MIC6) is a potential vaccine candidate against toxoplasmosis in mice | |
| EP0594743B1 (en) | Continuous cell line and vaccine against avian coccidia | |
| JP2009077713A (ja) | アイメリア・マキシマ（Ｅｉｍｅｒｉａｍａｘｉｍａ）の配偶子母細胞由来の組換え５６及び８２ｋＤａ各抗原をコードする核酸及びその使用 | |
| Daryani et al. | Electrophoretic patterns of Toxoplasma gondii excreted/secreted antigens and their role in induction of the humoral immune response | |
| WO2026092023A1 (zh) | 一种基因缺失的重组弓形虫虫株疫苗及其构建方法 | |
| Matos et al. | A prime-boost immunization with Tc52 N-terminal domain DNA and the recombinant protein expressed in Pichia pastoris protects against Trypanosoma cruzi infection | |
| Pernas et al. | Association of host mitochondria with the parasitophorous vacuole during Toxoplasma infection is not dependent on rhoptry proteins ROP2/8 | |
| Huynh et al. | Trans‐genera reconstitution and complementation of an adhesion complex in Toxoplasma gondii | |
| AU2005207647B2 (en) | Apicomplex vaccine strains of a family of sarcocystidae | |
| Zhao et al. | Protective efficacy of pVAX-RON5p against acute and chronic infections of Toxoplasma gondii in BALB/c mice | |
| Dongchao et al. | Loss of rhoptry protein 9 impeded Toxoplasma gondii infectivity | |
| US20160166662A1 (en) | Use of attenuated strains of parasites for the prevention or treatment of pathologies associates with an apicomplexan | |
| Li et al. | Protective effect against toxoplasmosis in BALB/C mice vaccinated with recombinant Toxoplasma gondii CDPK3, GRA35, and ROP46 protein cocktail vaccine | |
| US5393523A (en) | Plasmodium falciparum vaccine comprising a recombinant histidine-rich protein-HRP-II | |
| EP1307537B1 (en) | Neospora caninum isolate | |
| Zhang et al. | A novel Toxoplasma gondii thioredoxin (TgTrx1) is important for parasite fitness and virulence | |
| Vullo et al. | Serologic responses to Rhodococcus equi in individuals with and without human immunodeficiency virus infection | |
| EP2723355B1 (en) | Conditional knockout mutants of sortilin-like receptor in apicomplexan parasites and uses thereof | |
| CN119798456A (zh) | 一种靶向cd4+t细胞的微小隐孢子虫的表位多肽及其应用 | |
| Tang et al. | Characterization and Vaccine Potential of EtRON2L1-a Novel RON2 Paralog in Eimeria tenella | |
| Guo | Functional characterization of dense granule protein 9 in Toxoplasma gondii | |
| Nava | Defining Molecular Mechanism of Egress in Cryptosporidium | |
| Carrión | Comparative Immunology, Microbiology and Infectious Diseases | |
| Dogga et al. | Archive ouverte UNIGE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JAN 2016 BY DENNEMEYER + CO Effective date: 20141219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JAN 2017 BY DENNEMEYER + CO Effective date: 20151223 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JAN 2018 BY DENNEMEYER + CO Effective date: 20170112 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JAN 2019 BY DENNEMEYER + CO Effective date: 20171216 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JAN 2020 BY DENNEMEYER + CO Effective date: 20181220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JAN 2021 BY DENNEMEYER + CO Effective date: 20200109 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 JAN 2022 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20210104 |
|
| LAPS | Patent lapsed |